Selpercatinib: A narrative drug review
Authors:
Open Access
- 1 January 2024
- journal article
- Published by Wolters Kluwer Health in Cancer Research, Statistics, and Treatment
- Vol. 7 (1) , 82-90
Abstract
Rearranged during transfection ( RET ) alteration promotes oncogenesis in a few cancers. RET mutation positivity is seen in approximately 70% of medullary thyroid cancers, around 30% of differentiated papillary thyroid cancers, and 1-2% of non-small-cell lung cancers (NSCLC). To write this narrative drug review, we searched various websites like the United States Food and Drug Administration, PubMed, Google Scholar, UpToDate, and recently published papers in various international conferences using the search terms “RET,” “RET alteration,” “Retevmo,” “RET inhibitors,” and “selpercatinib.” We shortlisted 31 articles published between January 1980 and January 2024. We discuss the history, mechanism of action, resistance, pharmacodynamics, pharmacokinetics, dosing, toxicity, pivotal trials, and indications of selpercatinib. Selective RET inhibitors like selpercatinib are indicated in the treatment of RET -altered NSCLC and thyroid cancer.Keywords
This publication has 24 references indexed in Scilit:
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLCNew England Journal of Medicine, 2023
- Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancerCancer Treatment and Research Communications, 2023
- RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment LandscapeThe Oncologist, 2023
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutationsAnnals of Oncology, 2021
- Efficacy of Selpercatinib in RET -Altered Thyroid CancersNew England Journal of Medicine, 2020
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven MalignanciesJournal of Thoracic Oncology, 2020
- RET fusions in solid tumorsCancer Treatment Reviews, 2019
- Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- RET Gene and Its Implications for CancerJNCI: Journal of the National Cancer Institute, 1995
- Activation of a novel human transforming gene, ret, by DNA rearrangementCell, 1985